X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs VENUS REMEDIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES VENUS REMEDIES SUVEN LIFESCIENCES/
VENUS REMEDIES
 
P/E (TTM) x 19.1 -0.9 - View Chart
P/BV x 3.7 0.1 5,561.8% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 SUVEN LIFESCIENCES   VENUS REMEDIES
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-18
VENUS REMEDIES
Mar-18
SUVEN LIFESCIENCES/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs251126 199.2%   
Low Rs15561 253.7%   
Sales per share (Unadj.) Rs49.1301.8 16.3%  
Earnings per share (Unadj.) Rs9.7-24.9 -39.1%  
Cash flow per share (Unadj.) Rs11.42.5 447.7%  
Dividends per share (Unadj.) Rs1.500-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs60.3293.3 20.6%  
Shares outstanding (eoy) m127.2812.34 1,031.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.10.3 1,333.1%   
Avg P/E ratio x20.9-3.8 -555.4%  
P/CF ratio (eoy) x17.836.7 48.5%  
Price / Book Value ratio x3.40.3 1,055.6%  
Dividend payout %15.40-   
Avg Mkt Cap Rs m25,8251,154 2,238.3%   
No. of employees `0001.10.9 115.9%   
Total wages/salary Rs m613393 155.9%   
Avg. sales/employee Rs Th5,832.64,026.1 144.9%   
Avg. wages/employee Rs Th571.5425.0 134.5%   
Avg. net profit/employee Rs Th1,153.8-331.8 -347.7%   
INCOME DATA
Net Sales Rs m6,2533,724 167.9%  
Other income Rs m23323 1,034.2%   
Total revenues Rs m6,4853,747 173.1%   
Gross profit Rs m1,982395 502.0%  
Depreciation Rs m213338 63.0%   
Interest Rs m46354 13.1%   
Profit before tax Rs m1,955-275 -710.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m71832 2,272.9%   
Profit after tax Rs m1,237-307 -403.0%  
Gross profit margin %31.710.6 299.0%  
Effective tax rate %36.7-11.5 -320.1%   
Net profit margin %19.8-8.2 -240.0%  
BALANCE SHEET DATA
Current assets Rs m5,6222,638 213.2%   
Current liabilities Rs m1,1682,305 50.7%   
Net working cap to sales %71.28.9 796.7%  
Current ratio x4.81.1 420.7%  
Inventory Days Days81135 60.1%  
Debtors Days Days3646 77.5%  
Net fixed assets Rs m3,3254,871 68.3%   
Share capital Rs m127123 103.2%   
"Free" reserves Rs m7,5473,496 215.9%   
Net worth Rs m7,6743,619 212.0%   
Long term debt Rs m141,374 1.0%   
Total assets Rs m9,1357,509 121.7%  
Interest coverage x43.20.2 19,386.4%   
Debt to equity ratio x00.4 0.5%  
Sales to assets ratio x0.70.5 138.0%   
Return on assets %14.00.6 2,225.0%  
Return on equity %16.1-8.5 -190.1%  
Return on capital %26.01.6 1,645.5%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m5,0660-   
Fx outflow Rs m2,001517 387.5%   
Net fx Rs m3,065-517 -593.4%   
CASH FLOW
From Operations Rs m699514 136.0%  
From Investments Rs m-6-123 5.0%  
From Financial Activity Rs m-577-387 149.1%  
Net Cashflow Rs m1164 2,769.0%  

Share Holding

Indian Promoters % 63.4 32.9 193.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.2 -  
FIIs % 0.0 0.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 66.4 55.0%  
Shareholders   37,287 20,121 185.3%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   FDC LTD.  UNICHEM LAB  CIPLA  ELDER PHARMA  ALEMBIC LTD  

Compare SUVEN LIFESCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 318 Points Lower; Auto and Metal Stocks Witness Selling(Closing)

India share markets continued to witness selling pressure during closing hours and ended their day on a negative note.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Jul 18, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES - PIRAMAL ENTERPRISES COMPARISON

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS